奥沙利铂联合紫杉醇、5-氟尿嘧啶治疗中晚期大肠癌的临床观察  

Oxaliplatin Combined with Paclitaxel and Fluorouracil for Advanced Colorectal Cancer: Clinical Observation

作　　者：董虹亮[1] 梁建群[1] 

机构地区：[1]泸州医学院附属医院普外科,泸州市646000

出　　处：《中国药房》2008年第20期1568-1570,共3页China Pharmacy

摘　　要：目的:观察奥沙利铂联合紫杉醇、5-氟尿嘧啶治疗中晚期大肠癌的临床疗效、毒副反应。方法:将189例中晚期大肠癌患者随机分成治疗组94例(奥沙利铂联合紫杉醇、5-氟尿嘧啶组)和对照组95例(奥沙利铂联合5-氟尿嘧啶组)进行对照观察。21d为1个周期,全部病例均治疗3个周期。结果:治疗组总有效率54.3%,毒副反应轻;对照组总有效率40.0%,毒副反应相对较重(P<0.05)。结论:奥沙利铂联合紫杉醇、5-氟尿嘧啶治疗中晚期大肠癌疗效显著,毒副反应可耐受。OBJECTIVE： To investigate the clinical curative effect and adverse reaction of oxaliplatin combined with paclitaxel and fluorouracil in the treatment of advanced colorectal cancer. METHODS： 189 cases with advanced colorectal cancer were randomly divided into two groups： Group A（n = 94） received oxaliplatin combined with paclitaxel and fluorouracil, and Group B（n = 95） to receive oxaliplatin combined with fluorouracil. Both groups were treated with 3 cycles （21 days in every cycle）. RESULTS： The total effective rate in Group A was 54.3% versus 40.0% in Group B; and the toxicity in Group A was less severe than in Group B（P〈0.05）. CONCLUSION： Oxaliplatin combined with paclitaxel and fluorouracil had remarkable efficacy yet tolerable side effects in patients with advanced colorectal cancer.

关 键 词：奥沙利铂 紫杉醇 5-氟尿嘧啶 中晚期大肠癌 联合化疗 

分 类 号：R979.1[医药卫生—药品] R969.4[医药卫生—药学]